Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patientsYu Sawada, Tetsuya Nakatsura, Masaru Konishi et al.|OncoImmunology|2016Cited by 178
Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccinationYu Sawada, Tetsuya Nakatsura, Toshiaki Yoshikawa et al.|Human Vaccines & Immunotherapeutics|2013Cited by 30
Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinomaKazuya Ofuji, Tetsuya Nakatsura, Keigo Saito et al.|Oncotarget|2016Cited by 28
Predictive model for survival after liver resection for noncolorectal liver metastases in the modern era: a Japanese multicenter analysisTaiga Wakabayashi, Masakazu Yamamoto, Taizo Hibi et al.|Journal of Hepato-Biliary-Pancreatic Sciences|2019Cited by 13
Abstract CT115: Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patientsYu Sawada, Tetsuya Nakatsura, Toshiaki Yoshikawa et al.|Cancer Research|2015Cited by 0